Oxfam says that patents laws denying the poor access to crucial medicines.
Non-governmental organisations feared a victory for Novartis would set a precedent for other pharmaceutical companies seeking patent protection for essential medicines.
‘New and improved’
“Our case is solely about safeguarding intellectual property, this is not about patient access.”
India‘s patent law, which came into effect on January 1, 2005, allows patents for products that represent new inventions after 1995, the year India joined the World Trade Organisation, or for an updated drug that shows greater efficacy.
The Indian government rejected a Novartis attempt to patent a new version of its popular leukaemia drug Gleevec.
Novartis insists that its improved drug is more easily absorbed by the body.
But Indian drug companies and aid groups say Gleevec, which is known in Europe and India as Glivec, is a new form of an old drug invented before 1995.
Several Indian pharmaceutical companies already make generic copies of Gleevec, but sell it at a tenth of the $2,600 price for a monthly dose charged by the Swiss company.
Novartis says it has a record in funding health care projects for the poor which cost it hundreds of millions of dollars.
|Activists say a change in drug patent law
could leave millions without treatment [AFP]
In a statement in January, the company said: “Our case is solely about safeguarding intellectual property. This is not about patient access. With our well-regarded record in social responsibility, we are surprised that some groups are confusing the issue in India.”
But health campaign groups say that if drug companies like Novartis are allowed to patent their products, cheap copies will dry up, and the poor will go untreated.
International aid groups Medecins Sans Frontieres and Oxfam collected more than 250,000 signatures for a petition to Novartis asking it to drop its case.
Campaigners are also looking to the Indian government for help and sympathetic politicians say patent laws simply should not apply to drugs at all.
Novartis has defended its position and said it will offer its leukaemia drug for free to patients who cannot afford it.